Exacerbations in COPD: What’s the risk?
How does an exacerbation affect patient quality of life and lung function?
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
has been added to your basket
59
Watch Professor Paul Jones, GSK Global Medical Expert, give an overview of the IMPACT trial which aimed to determine the patient benefit that could be achieved by adding an inhaled corticosteroid to dual bronchodilator therapy.
Trelegy Ellipta Prescribing Information
Anoro ▼ Ellipta (umeclidinium/vilanterol) Prescribing Information
Relvar Ellipta (Fluticasone furoate/vilanterol) Prescribing Information
Seretide Accuhaler 50/500 (salmeterol/fluticasone propionate) Prescribing Information
Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.2
Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)6
Relvar Ellipta 92/22mcg is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilation therapy3
Seretide (50 micrograms salmeterol and 500 micrograms fluticasone propionate) is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
BD, twice daily; BUD, budesonide; CAT, COPD assessment test; FEV1, forced expiratory volume in one second; FF/UMEC/VI, fluticasone furoate, umeclidinium, vilanterol; FOR, formoterol; ICS, inhaled corticosteroid; ITT, intent-to-treat; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; OD, once daily; QoL, quality of life; SGRQ, St George’s Respiratory Questionnaire; ARR, absolute risk reduction
References
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
October 2022 | PM-GB-FVU-WCNT-200013 (V7.0)